Navigation Links
Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
Date:6/16/2008

SAN DIEGO, June 16 /PRNewswire/ -- Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow(R) Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today. The GRAVITAS trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify patients that exhibit a low response to antiplatelet therapy who are at risk for adverse cardiac events, and prove that these at-risk patients will benefit from tailored antiplatelet therapy.

Various studies have shown that there is variability in how patients respond to antiplatelet therapy, and that up to 30% are non-responsive to antiplatelet medication, such as clopidogrel (Plavix(R)). These patients have a high degree of platelet reactivity and, as a result, are at greater risk of a major adverse cardiac event (MACE), such as cardiovascular death, myocardial infarction or stent thrombosis. With other medications such as statins, insulin and anticoagulants, patients benefit from individually tailored dosing to adequately manage their condition. The GRAVITAS trial will be the first trial conducted to demonstrate that patient outcomes are improved when dosing is tailored to the patient's response to clopidogrel as determined using the VerifyNow P2Y12 test.

The GRAVITAS trial is a double-blind, placebo-controlled, randomized trial that employs the VerifyNow P2Y12 test to classify patients undergoing percutaneous coronary intervention receiving a drug-eluting stent as "responsive" or "non-responsive" to clopidogrel. The trial's primary purpose is to evaluate whether patients (identified as non-responders) that are randomized to a tailored treatment have fewer adverse cardiac events than non-responders randomized to receive standard therapy. The study will involve screening approximately 7000 patients at 60-70 investigational centers in the United States and Canada, and enrollment is expected to be complete in 2009.

Matthew J. Price, MD,
'/>"/>

SOURCE Accumetrics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
2. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
3. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
4. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
5. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. XTENT Announces European Regulatory Update
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
10. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
11. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye today reported financial results for the second quarter ... , Net Sales of $18.7 Million Down 7% from ... $2.1 Million from the Weakening Euro and Yen , ... , APAC Sales Down 1% Including Korea - Up ...
(Date:7/29/2015)... 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the second quarter ended June 30, 2015. ... HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s ... life cycle management of our products set the stage ... Financial Highlights , Total net product ...
(Date:7/29/2015)... NEWARK, Calif. , July 29, 2015 /PRNewswire/ ... "Company") today announced that its Board of Directors, ... its independent financial and legal advisors, has unanimously ... non-binding proposal from Horizon Pharma plc (NASDAQ: ... outstanding shares of Depomed in an all-stock transaction ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13
... PARK, Calif., March 22, 2011 Telome Health, Inc. ... property portfolio. THI will provide telomere length data from ... health monitoring. THI leverages the predictive ... protective caps at the ends of chromosomes, to assess ...
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
Cached Medicine Technology:Telome Health, Inc. Launches With Exclusive IP Portfolio 2Telome Health, Inc. Launches With Exclusive IP Portfolio 3Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3
(Date:7/29/2015)... ... July 29, 2015 , ... Angelo’s FabriClean, an area ... service: water damage restoration of carpets and rugs. The company will now reverse the ... commercial clients. , An overflowing overhead tank, rain leaking through an accidently left ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than ... service providers of children living with autism will converge upon Penn State to ... , The National Autism Conference will be held Aug. 3-6 at the ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... ... Fitness as a sponsor, with its Topricin® Pain Relief and Healing Cream designated ... a firefighter-founded web-based organization that is actively addressing Line of Duty Deaths (LODD) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... This year, ... record-setting precipitation levels this spring. And, where there is water, mold is not far ... property, offers tips for protecting against water and mold damage. Paul Davis is regularly ...
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering a nationally ... Kalamazoo Strength & Conditioning. , The name change coincides with the release of ... training center over the past three years,” according to Jack Kelly, the center’s ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... received a $1.6 million grant from the National Cancer ... by the body,s immune system, allowing cancer to develop ... Health grant will enable researchers led by Alex Y. ... biomedical engineering at the School of Medicine, and a ...
... , THURSDAY, March 31 (HealthDay News) -- There may ... a common congenital heart defect, a new study suggests. U.S. ... diagnosed with migraines and treated at the Primary Children,s Medical Center ... team checked each child,s heart for a patent foramen ovale (PFO) ...
... immune tolerance field continues to grow. Following the ... October 2009, the Second International Conference on Immune ... their latest research and insights into the mechanisms ... transplantation, autoimmune diseases, inflammation and cancer. This Conference ...
... WEST LAFAYETTE, Ind. - Eating fewer, regular-sized meals with higher ... than eating smaller, more frequent meals, according to new research ... amounts of protein, men who were trying to lose weight ... in late-night desire to eat and had fewer thoughts of ...
... is growing evidence that the risk factors for ... risk factors for developing addiction in adolescence are ... is associated with the highest addiction risk. Traits ... behavioral disinhibition, and devaluation of the future negative ...
... 31 (HealthDay News) -- An antibacterial agent that,s an ingredient ... in the bodies of fish, finds a new study. ... concerns due to its potential hormone-disrupting effects. Bioaccumulation occurs ... unable to metabolize and excrete the chemical quickly enough, allowing ...
Cached Medicine News:Health News:Case Western Reserve receives $1.6M to study tumor cells and immune cell detection 2Health News:2nd International Conference on Immune Tolerance 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 3Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 4Health News:Different genes influence smoking risk during adolescence and adulthood 2Health News:Antibacterial Soap Additive Accumulates in Fish: Study 2
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... is an automated, turbidimetric, whole- blood assay ... the ability of activated platelets to bind ... of the VerifyNow IIb/IIIa assay device contains ... this analysis. Within the well is an ...
... The Company's first commercial product is ... with single-use, disposable assay devices . The ... products are direct use of a vacuum-type ... a result in minutes. VerifyNow IIb/IIIa, the ...
... ComboMap system provides both pressure and ... singly or in a combined screen ... SmartWire and Volcano's unique Doppler FloWire. ... valuable tools to assess ambiguous or ...
Medicine Products: